201. Genetic variation in Charcot-Marie-Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy.
- Author
-
Chen Y, Fang F, Kidwell KM, Vangipuram K, Marcath LA, Gersch CL, Rae JM, Hayes DF, Lavoie Smith EM, Henry NL, Beutler AS, and Hertz DL
- Subjects
- Adult, Aged, Antineoplastic Agents, Phytogenic adverse effects, Cohort Studies, Female, Humans, Male, Middle Aged, Prospective Studies, Charcot-Marie-Tooth Disease drug therapy, Charcot-Marie-Tooth Disease genetics, Genetic Variation genetics, Paclitaxel adverse effects, Polyneuropathies chemically induced, Polyneuropathies genetics
- Abstract
Aim: This study explored whether inherited variants in genes causing the hereditary neuropathy condition Charcot-Marie-Tooth disease are associated with sensitivity to paclitaxel-induced peripheral neuropathy (PN). Patients & methods: Hereditary neuropathy genes previously associated with risk of paclitaxel-induced PN were sequenced in paclitaxel-treated patients. Eight putative genetic predictors in five hereditary neuropathy genes ( ARHGEF10 , SBF2 , FGD4 , FZD3 and NXN ) were tested for association with PN sensitivity after accounting for systemic exposure and clinical variables. Results: FZD3 rs7833751, a proxy for rs7001034, decreased PN sensitivity (additive model, β = -0.41; 95% CI: -0.66 to -0.17; p = 0.0011). None of the other genetic predictors were associated with PN sensitivity. Conclusion: Our results support prior evidence that FZD3 rs7001034 is protective of PN and may be useful for individualizing paclitaxel treatment to prevent PN.
- Published
- 2020
- Full Text
- View/download PDF